Balance of chemokine entry and exit signals controls T cell accumulation in skin

趋化因子进入和退出信号的平衡控制皮肤中 T 细胞的积累

基本信息

  • 批准号:
    7222766
  • 负责人:
  • 金额:
    $ 12.85万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-04-12 至 2011-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): With the proposed Research Scientist Development Award, the applicant will build upon her prior experience in antigen and chemokine regulation of T cell migration and immunity to study T cell recirculation using in vivo models of skin inflammation. The laboratory of Andrew D. Luster, MD, PhD, at Massachusetts General Hospital will provide a stimulating environment to further the candidate's scientific development toward achieving her ultimate goal of independent investigation. The proposed study will provide the applicant with the opportunity to examine the interplay of chemokines in regulating the migratory fate of T cells in inflamed skin. Both T cell entry into tissues from the bloodstream and T cell exit from tissues into afferent lymph control the accumulation of lymphocytes at peripheral sites and their participation in immune/inflammatory reactions. The roles of several individual chemokines in directing the traffic of T cell entry and exit from the skin have been characterized. However, the interplay between different chemokine signals in controlling the transit of T cells through skin remains completely unknown. Here, we hypothesize that a balance in chemokine entry, retention, and exit signals regulates the accumulation of effector/memory T cells within skin. In these proposed studies, we will use delayed type hypersensitivity and allergic dermatitis models to 1) Investigate the mechanisms that regulate the accumulation of effector/memory T cells in inflamed skin. We will track the migration of responding T cells by labelling cutaneous T cells in vivo with CFSE and determine the chemokine receptor expression profiles of CFSE+ T cells that remain in the skin, versus those that continue to migrate through the skin to draining lymph nodes; 2) Determine the consequence of effector/memory T cell antigen recognition in peripheral tissues on their expression of chemokine receptors and their retention in skin versus migration into afferent lymph; 3) Attempt to override the balance in chemokine receptor responsiveness using genetically altered T cells and mice that either lack or overexpress chemokine receptors or chemokine ligands. Results from these studies should further elucidate the mechanisms that regulate T cell transit through tissues and might benefit the treatment of pathological conditions in which large T cell infiltrates accumulate inappropriately in peripheral tissues.
描述(由申请人提供):通过拟议的研究科学家发展奖,申请人将利用其先前在T细胞迁移和免疫的抗原和趋化因子调节方面的经验,使用皮肤炎症的体内模型研究T细胞再循环。Andrew D.马萨诸塞州总医院的医学博士,博士将提供一个刺激的环境,以进一步促进候选人的科学发展,实现她独立调查的最终目标。拟议的研究将为申请人提供机会,以检查趋化因子在调节炎症皮肤中T细胞迁移命运中的相互作用。 T细胞从血流进入组织和T细胞从组织离开进入传入淋巴都控制淋巴细胞在外周部位的积累及其参与免疫/炎症反应。几个单独的趋化因子在指导T细胞进入和离开皮肤的交通中的作用已经被表征。然而,不同趋化因子信号在控制T细胞通过皮肤的转运中的相互作用仍然完全未知。在这里,我们假设趋化因子进入,保留和退出信号的平衡调节效应/记忆T细胞在皮肤内的积累。在这些拟议的研究中,我们将使用迟发型超敏反应和过敏性皮炎模型来1)研究调节炎症皮肤中效应/记忆T细胞积累的机制。 我们将通过用CFSE在体内标记皮肤T细胞来跟踪应答T细胞的迁移,并确定保留在皮肤中的CFSE+ T细胞与继续通过皮肤迁移到引流淋巴结的CFSE+ T细胞的趋化因子受体表达谱; 2)确定效应器的后果/外周组织中的记忆T细胞抗原识别对其趋化因子受体表达的影响及其在皮肤中的保留与迁移到传入淋巴中的关系; 3)尝试使用基因改变的T细胞和缺乏或过度表达趋化因子受体或趋化因子配体的小鼠来推翻趋化因子受体反应性的平衡。这些研究的结果应进一步阐明调节T细胞通过组织转运的机制,并可能有利于治疗大T细胞浸润在外周组织中不适当积累的病理条件。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SHANNON K BROMLEY其他文献

SHANNON K BROMLEY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SHANNON K BROMLEY', 18)}}的其他基金

Effect of Th2-type microenvironment on CD8 TRM-mediated protection from infection
Th2型微环境对CD8 TRM介导的感染保护作用的影响
  • 批准号:
    10624943
  • 财政年份:
    2022
  • 资助金额:
    $ 12.85万
  • 项目类别:
Effect of allergic asthma on CD8+ TRM-mediated protection from infection
过敏性哮喘对 CD8 TRM 介导的感染保护作用的影响
  • 批准号:
    10495217
  • 财政年份:
    2021
  • 资助金额:
    $ 12.85万
  • 项目类别:
Effect of allergic asthma on CD8+ TRM-mediated protection from infection
过敏性哮喘对 CD8 TRM 介导的感染保护作用的影响
  • 批准号:
    10353929
  • 财政年份:
    2021
  • 资助金额:
    $ 12.85万
  • 项目类别:
Mechanisms of CD49a Expression and Resident Memory T Cell Formation in Skin.
皮肤中 CD49a 表达和常驻记忆 T 细胞形成的机制。
  • 批准号:
    9302659
  • 财政年份:
    2016
  • 资助金额:
    $ 12.85万
  • 项目类别:
Bromley Pilot and Feasibility Project
布罗姆利试点和可行性项目
  • 批准号:
    7393279
  • 财政年份:
    2007
  • 资助金额:
    $ 12.85万
  • 项目类别:
Balance of chemokine entry and exit signals controls T cell accumulation in skin
趋化因子进入和退出信号的平衡控制皮肤中 T 细胞的积累
  • 批准号:
    7590369
  • 财政年份:
    2006
  • 资助金额:
    $ 12.85万
  • 项目类别:
Balance of chemokine entry and exit signals controls T cell accumulation in skin
趋化因子进入和退出信号的平衡控制皮肤中 T 细胞的积累
  • 批准号:
    7393238
  • 财政年份:
    2006
  • 资助金额:
    $ 12.85万
  • 项目类别:
Balance of chemokine entry and exit signals controls T cell accumulation in skin
趋化因子进入和退出信号的平衡控制皮肤中 T 细胞的积累
  • 批准号:
    7789488
  • 财政年份:
    2006
  • 资助金额:
    $ 12.85万
  • 项目类别:
Balance of chemokine entry and exit signals controls T cell accumulation in skin
趋化因子进入和退出信号的平衡控制皮肤中 T 细胞的积累
  • 批准号:
    7085722
  • 财政年份:
    2006
  • 资助金额:
    $ 12.85万
  • 项目类别:
CCR7 and CCR9 in T Cell Development and Trafficking
T 细胞发育和运输中的 CCR7 和 CCR9
  • 批准号:
    6695301
  • 财政年份:
    2003
  • 资助金额:
    $ 12.85万
  • 项目类别:

相似海外基金

Identifying the Most Effective Adjuvant(s) for Leading Group A Streptococcal Vaccine Antigens in Preclinical Mouse and Nonhuman Primate Models
在临床前小鼠和非人灵长类动物模型中确定 A 组链球菌疫苗抗原最有效的佐剂
  • 批准号:
    10577066
  • 财政年份:
    2023
  • 资助金额:
    $ 12.85万
  • 项目类别:
Lymph node-targeted codelivery of albumin-binding peptide antigens and di-adjuvant for melanoma combination immunotherapy
用于黑色素瘤联合免疫治疗的白蛋白结合肽抗原和双佐剂的淋巴结靶向共递送
  • 批准号:
    10522591
  • 财政年份:
    2022
  • 资助金额:
    $ 12.85万
  • 项目类别:
Lymph Node-Targeted Codelivery of Albumin-Binding Peptide Antigens and Di-Adjuvant for Melanoma Combination Immunotherapy
用于黑色素瘤联合免疫治疗的白蛋白结合肽抗原和双佐剂的淋巴结靶向共递送
  • 批准号:
    10884052
  • 财政年份:
    2022
  • 资助金额:
    $ 12.85万
  • 项目类别:
Establishment of postoperative adjuvant immunotherapy using peptide pool of tumor antigens in advanced esophageal cancer
晚期食管癌肿瘤抗原肽库术后辅助免疫治疗的建立
  • 批准号:
    15K10100
  • 财政年份:
    2015
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of cancer vaccine using adjuvant function encrypted artificial antigens
使用佐剂功能加密人工抗原开发癌症疫苗
  • 批准号:
    26430172
  • 财政年份:
    2014
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Alpha-galactosycleramide as a mucosal adjuvant for HIV antigens
α-半乳糖酰胺作为 HIV 抗原的粘膜佐剂
  • 批准号:
    7849955
  • 财政年份:
    2009
  • 资助金额:
    $ 12.85万
  • 项目类别:
Alpha-galactosycleramide as a mucosal adjuvant for HIV antigens
α-半乳糖酰胺作为 HIV 抗原的粘膜佐剂
  • 批准号:
    7627172
  • 财政年份:
    2009
  • 资助金额:
    $ 12.85万
  • 项目类别:
RECOMBINANT MIF AS AN ADJUVANT FOR HIV ANTIGENS
重组 MIF 作为 HIV 抗原的佐剂
  • 批准号:
    2068228
  • 财政年份:
    1992
  • 资助金额:
    $ 12.85万
  • 项目类别:
RECOMBINANT MIF AS AN ADJUVANT FOR HIV ANTIGENS
重组 MIF 作为 HIV 抗原的佐剂
  • 批准号:
    3548034
  • 财政年份:
    1992
  • 资助金额:
    $ 12.85万
  • 项目类别:
RECOMBINANT MIF AS AN ADJUVANT FOR HIV ANTIGENS
重组 MIF 作为 HIV 抗原的佐剂
  • 批准号:
    3548033
  • 财政年份:
    1992
  • 资助金额:
    $ 12.85万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了